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The metabolism of enkephalin peptides was studied in human cerebrospinal fluid. The degradation rates 
of (Leu)-enkephalin and (Leu)-enkephalin-Arg6 were compared and the latter was degraded at a IO-fold 
higher rate. The major enzyme activity was investigated by M, determination and inhibition experiments, 
showing marked similarity with angiotensin-converting enzyme. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Analysis of peptides in human cerebrospinal 
fluid (CSF) is becoming of clinical interest. Peptide 
levels are influenced by several factors including 
enzyme activities. We have previously found that 
human CSF contains greater amounts of the C- 
terminally extended, basic enkephalyl peptides 
than of the enkephalins themselves [l]. This may 
seem unexpected if the extended peptides are the 
precursors and the enkephalins are the active signal 
substances released at the synapses. One factor 
which might influence peptide levels as measured 
in CSF is the presence of enzymes in the CSF itself. 
Enkephalin degradation has previously been 
observed in CSF and ascribed to nonspecified 
aminopeptidase, dipeptidylaminopeptidase and 
dipeptidylcarboxypeptidase activities [2]. 
The CSF was obtained by lumbar puncture from 
patients, undergoing investigation for suspected 
increased intracranial pressure. Total protein con- 
tent was within the normal range. The tritiated 
peptides were obtained from Amersham, England, 
and all reference peptides from Bachem, Buben- 
dorf, Switzerland. Chemicals and solvents were of 
reagent grade from usual sources. 
The aim of this study was to compare the 
metabolic stabilities of the enkephalins and the 
basic enkephalyl peptides in CSF. The peptides 
chosen for the comparison were (Leu)-enkephalin 
and (Leu)-enkephalin-Arg6. These peptides and 
their metabolic products were more easily 
separated by HPLC, than the corresponding 
methionine-containing enkephalyl peptides (fig. 1). 
The CSF material was desalted by a Sephadex 
G-25 M (Pharmacia) column, PD-10, bed volume 
9 ml. The protein fraction was collected and 
lyophilized. It was redissolved in the original 
volume of 0.2 M Tris-HCl buffer, pH 7.4, and in- 
cubated with 5.9 x 10e8 M [3H](Leu)-enkephalin 
or [3H](Leu)-enkephalin-Arg6 for different time 
periods at 37°C. The reactions were stopped by 
adding aliquots of the reaction mixture to 150 ~1 
ice-cold EtOH, followed by centrifugation (Beck- 
man microfuge B) for 5 min to remove the pro- 
teins. The supernatant was mixed in Eppendorf 
tubes with carrier peptides, including all potential 
metabolites from the substrate. 
Separation of the degradation products was per- 
formed in a Hewlett Packard 1084 B liquid 
chromatograph with a Supelcosil LC-18-DB col- 
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umn (250 x 4.6 mm) (fig.1). The smallest 
fragments Tyr, Tyr-Gly and Tyr-Gly-Gly were 
resolved by isocratic elution for 40 min with 
0.04% trifluoroacetic acid/HzO, followed by a 
30 min linear gradient of methanol (15-45%) in 
0.04% trifluoroacetic acid, which eluted the longer 
peptides. The flow rate was 1.0 ml/min and frac- 
tions of 1.0 ml were collected and the amount of 
radioactivity determined by liquid scintillation 
counting. 
A4, determination was made on a Sephacryl 
S-200 column (2 x 60 cm), calibrated with proteins 
of known Mr: y-globulin, A4, 160000; bovine 
serum albumin, M, 68000; human ,&-casein, M, 
26000; cytochrome c, M, 13 000. The flow rate was 
20 ml/h with 0.04 M NH4HC03 as eluent. Frac- 
tions of 2 ml were collected. Lyophilized aliquots 
of the fractions were redissolved and incubated 
with 7 PM (Leu)-enkephalin-Arg6 and tracer 
amounts of tritiated (Leu)-enkephalin-Arg6. The 
metabolic products were analyzed as before. 
Inhibition experiments were performed with 
7 PM (Leu)-enkephalin-Arg6 and tracer amounts 
of the tritiated peptide as substrate. The peptides 
used as inhibitors were added in concentrations of 
700 PM; EDTA, 10 ,uM; phosphoramidone, 
1OpM; captopril, 10pM; MK-422 (the active 
diacid of enalapril), 0.1 or 100 PM. The incubation 
time was 60 min. Substrate and products as in- 
dicated were isolated by HPLC under the same 
conditions as in the previous series of experiments. 
TyrGlyGly TyrGly 
Fig. 1. Separation of (Leu)-enkephalin, (Leu)-enkeph- 
alin-Arg6 and their N-terminal fragments by HPLC. 
3. RESULTS AND DISCUSSION 
(Leu)-enkephalin was about lo-times more 
stable than (Leu)-enkephalin-Arg6 in CSF (cf. 
fig.2a and b). The major degradation products 
from (Leu)-enkephalin were Tyr and Tyr-Gly-Gly, 
indicating aminopeptidase and dipeptidylcarbox- 
ypeptidase activities. The major route of 
metabolism of (Leu)-enkephalin-Arg6 was the 
cleavage of the Phe4-Leu’ bond, giving rise to 
Tyr-Gly-Gly-Phe and Leu-Arg. Formation of these 
fragments was responsible for the higher degrada- 
tion rate of the hexapeptide. Only small amounts 
of Tyr, Tyr-Gly and (Leu)-enkephalin were 
generated. Thus, the higher concentration of 
(Leu)-enkephalin-Arg6 than (Leu)-enkephalin 
generally observed in CSF samples [l] cannot be 
explained in terms of differences in CSF degrada- 
tion activities. Considering other possibilities for 
this difference, enzymes in the synaptic cleft may 
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Fig.2. Time course of (a) (Leu)-enkephalin and (b) 
(Leu)-enkephalin-Arg6 degradation in human CSF. 
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be more specific for the pentapeptides, allowing 
the C-terminally extended hexapeptides to diffuse 
out and reach the CSF in greater amounts, 
A characterization of the enzyme activity was 
performed by adding different inhibitors to the in- 
cubation mixture (fig.3). EDTA, a rne~ll~“e~~e 
inhibitor, compfetely blocked tetrapeptide forma- 
tion. Phosphoramid~~e, which is an enkephalinase 
inhibitor, had a very small inhibitory effect, show- 
ing that enkephalinase is not a very impartant en- 
zyme in CSF, for the degradation of the hexapep- 
tide. The poor enkephahnase activity is also 
observed as a low rate of (Leu~~enkeph~in 
degradation (fig.2a). The rate of formation of Tyr- 
Gly-Gly by enkephalinase or other enzymes is less 
than that of Tyr formation. 
A possible candidate for the rapid degradation 
of the hexapeptide, angiotensin-converting enzyme 
(ACE), has previously been identified in human 
CSF [3]. The Mr of the CSF enzyme was assessed 
by chromatography and found to be 140000, 
which is the same as that reported for ACE in lung 
[4]. When captopril and MK-422, both reiatively 
specific inhibitors of ACE 151, were present, no 
Fig.3. Inhibition experiments. Effects of various enzyme 
inhibitors and peptides on the enzymatic formation of 
(Leu)~nkephalin, Tyr-Gly-GIy-Phe and smaller N- 
terminal fragments of (Leu)-enkcphaIin-Argo, C, 
control; Pho, phosp~oramidon (10 PM); Cap, captopril 
(IO pM); MK (I), MK 422 (100,~M); MK (2), MK 422 
(0.1 ,uM); SP, substance P; L-E, (Leu)-enkephalln; L-E- 
Arg6, (Leu)-enkephalin-Arg”; M-E-Lys6, (Met)-enkeph- 
alin-Lys6; M-E-Arg6Phe7, (Met)-enkephalin-Arg6Phe7. 
formation of Tyr-Gly-Gly-Phe was observed 
(fig.3). These results strongly support the conten- 
tion that the enzyme responsible for the high 
degradation rate of enkephalyl peptides is ACE. 
To investigate further the enzymatic conversion 
of (Leu~-enkephalin-Argon related peptides such as 
(Leu~-~nkephalin~ ( et~~e~kepha~n_Lys~~ (Met)- 
enk~halin-Arg~Phe’ were added as inhibitors in a 
100-fold molecular excess (fig.3). (Let@enkephalin 
had a very small inhibitory effect on the formation 
of the tetrapeptide from the hexapeptide, in- 
dicating that (Leu)-enkephalin-Arg6 is a much bet- 
ter substrate than (Leu)-enke~halin~ which has also 
been reported for ACE from rat brain [6f_ (Met)- 
enkephalin-Lys~ and (Met~-enkephalin-Arg~Ph~7 
were both good inhibitors and lowered tetrapep- 
tide formation by 78 and 92%, respectively, as 
compared with the inhibition by (Leu)-enkephalin- 
Arg6 (= 84%), when added in the same molecular 
excess. 
The hydrolysis of substance P has been reported 
to be catalyzed by ACE [7,8]. Therefore it was 
tried as inhibitor, but it did not show any signifi- 
cant inhibitory effect on tetrapeptide formation, 
However, the rate of substance P conversion has 
been reported to be only about l/60 that of 
angiotensin I. 
Enzymes in CSF could potentially derive from 
tissues within the CNS, from choroid plexus and 
vasculature or even be of blood origin. However, 
in human choroid plexus the ACE activity is 
relatively low, while it is high in the caudate 
nucleus, even compared to the lung [9], favouring 
a neuronal origin of the ACE-like enzyme in CSF. 
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